StockrabitBrowse analysts
Analyst questions

Avnish Tiwari

Vaikarya Investment Managers
WINDLAS

Windlas Biotech Limited

All company calls
FY2027 Q1
11 Aug 2026
Open call
  1. Komal, can you articulate the gross margin performance, which we had this quarter? So, if a portion of Trade Generics mix has come down and which is typically a higher gross margin, so what might have from a mix point of view, helped our performance on gross margin? It's pretty remarkable performance. Any segment or any other factors added related to the API prices or anything?

    Read in transcript
  2. Okay. And sir, last question, how are the API prices are trending or experiencing -- you guys have experienced? Are they more stable zone now or they were a bit more volatile due to the crisis earlier? How are they behaving now?

    Read in transcript